Efficacy of a midwife-coordinated, individualized, and specialized maternity care intervention (ChroPreg) in addition to standard care in pregnant women with chronic disease: protocol for a parallel randomized controlled trial

CURRENT STATUS: ACCEPTED

Mie de Wolff
Rigshospitalet

Corresponding Author
ORCID: https://orcid.org/0000-0002-9483-6559

Marianne Johansen
Rigshospitalet

Anne Schoedt Ersboell
Nordsjaellands Hospital

Susanne Rosthoj
Kobenhavns Universitet

Anne Brunsgaard
Rigshospitalet

Julie Midtgaard
Kobenhavns Universitet

Ann Tabor
Rigshospitalet

Hanne Kristine Hegaard
Rigshospitalet

DOI:
10.21203/rs.2.143/v2

SUBJECT AREAS
General Medicine
Abstract

Background and objectives: The number of women of childbearing age with chronic diseases is rising. Evidence has shown that obstetric complications and poor psychological well-being are more prevalent among this group, in addition to these women reporting experiences of less than satisfactory care. More research is needed to investigate how to best meet the special needs of this group during pregnancy and postpartum. Previous research has shown that care coordination, continuity of care, woman-centered care and specialized maternity care interventions delivered to women with high-risk pregnancies can improve patient-reported outcomes, pregnancy outcomes, and be cost-effective. However, no previous trials have examined the efficacy and cost-effectiveness of such interventions among pregnant women with chronic diseases. This paper describes the protocol of a randomized controlled trial (RCT) of a midwife-coordinated, individualized and specialized maternity care intervention (ChroPreg) as an add-on to standard care for pregnant women with chronic diseases. Methods/design: This two-arm parallel group RCT study will be conducted from October 2018 – June 2020 at the Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Denmark. Pregnant women with chronic diseases are invited to participate; women will be randomized and allocated 1:1 to the ChroPreg intervention plus standard care or standard care alone. The ChroPreg intervention consists of three main components: 1. Coordinated and individualized care, 2. Additional ante- and postpartum consultations, and 3. Specialized midwives. The primary outcome is length of hospital stay (LOS) during pregnancy and postpartum period and secondary outcomes are: psychological well-being (the five-item World Health Organization Well-being Index, Edinburgh Postnatal Depression Scale, Cambridge Worry Scale), health-related quality of life (the 12-Item Short Form Survey), patient satisfaction (The Pregnancy and Childbirth Questionnaire), number of antenatal contacts, and pregnancy and delivery outcomes. Data is collected via patient-administered questionnaires and medical records. Discussion: This trial is anticipated to contribute to the field of knowledge on which planning of improved antenatal, intra- and postpartum care for women with chronic disease is founded.
In Denmark and worldwide, the number of individuals living with chronic disease is rising (1, 2) and more than one in three Danish adults live with one or more chronic diseases (1). The management and prevention of chronic disease is a worldwide, major public health problem worldwide a major public health problem and one of the issues most targeted by the World Health Organization (2). The number of pregnant women affected by chronic diseases such as autoimmune disease, cardiovascular disease, and endocrine disease is also rising; and in 2015, the prevalence in Denmark was 16% among pregnant women (3) and international studies report a prevalence between 16 and 27% (4, 5). The observed rise in chronic disease among pregnant women reflects the rise in chronic disease in the general population (1). Factors also contributing to this rise include the increasing age of childbearing women, improvements in medical and surgical treatment options, increased usage of assisted reproductive technologies, and improvements in diagnostic challenges with better registration of correct diagnoses (3, 6). Pregnant women with chronic diseases are comprise a vulnerable group. Overall, these women have a higher risk of preterm birth, pregnancy complications such as gestational diabetes and pre-eclampsia, operative deliveries, and postpartum depression and longer hospitalization during pregnancy and postpartum (5-9), while in addition to this, children of women with chronic diseases have a higher risk of low birth weight, low Apgar score, and birth defects (10-12). For some women the chronic disease may can be worsened by pregnancy (13), while though in others some cases of disease the women may experience remission from symptoms during pregnancy (10, 14). Furthermore, for some chronic diseases diseases such as sclerosis and rheumatoid arthritis, there is an increased risk of postpartum flares such as multiple sclerosis and rheumatoid arthritis (14-16). In qualitative studies, women with chronic diseases indicate that information given by caregivers can be uncoordinated and divergent (e.g. information about medication safety, mode of delivery and breastfeeding). Women also described less than satisfactory inadequate care from midwives and doctors in relation to discussing how to distinguish symptoms of pregnancy and what relates to the disease and to prepare women for what to expect during pregnancy (16). In addition to these experiences, women described expressed a general experience of “feeling abandoned” postpartum, and how support for and understanding of their needs
was lacking at the time of discharge (17, 18). The consequences of the increasing population of pregnant women with chronic diseases are numerous, including a higher demand on maternity care providers to skillfully manage pregnancies complicated by chronic diseases. Furthermore, this increase calls for all maternity care providers to provide coordinated care and consistent counselling (19-21) and to support the pregnant woman in her ability to manage her everyday life with a chronic disease both during pregnancy and postnatally as a new mother (18). It is therefore important that care providers apply highly specialized medical knowledge combined with an ability to provide psychosocial support in the care for this vulnerable group of pregnant women (6, 16, 22). Previous RCT studies that evaluated the effect of maternity care interventions for women with high-risk pregnancies have found that the following components had a positive effect on patient-reported outcomes such as patient satisfaction, obstetric, and health economic outcomes such as cost reduction and reduction in length of hospital stay: implementation of specialized multidisciplinary teams (20, 21, 23), care-coordination (19, 24), continuity of care (25), antenatal and postpartum telephone-support (26), and maternity care with focus on care transitions (22). Also, a study showed that length of hospital stay was increased for pregnant women with chronic disease compared to other pregnant women (9). In a review of RCT studies (22) the introduction of nurse specialists care during pregnancy and the postpartum period of pregnant women with epilepsy demonstrated a positive effect on satisfaction of care provided and a reduction in the length of hospital stay. The introduction of nurse specialists in the care during pregnancy and the postpartum period for pregnant women with epilepsy had a positive effect on satisfaction with the care provided and a reduction in the length of hospital stay was seen in a review of RCT studies (22). To our knowledge, no previous RCT has evaluated the effect of the implementation of a midwife-coordinated, individualized, and specialized maternity care intervention as an add-on intervention to standard care delivered to pregnant women with chronic diseases. In previous systematic reviews, the authors have addressed the need for trials that include patient-reported outcomes such as satisfaction with maternity care and psychological well-being during pregnancy and in the postpartum period with validated psychometric instruments (21, 27).
Aim
The aim of this RCT entitled the ChroPreg Trial, is to evaluate the efficacy of a midwife-coordinated, individualized and specialized maternity care intervention as an add-on to standard care for pregnant women with chronic diseases. The primary outcome is the length of hospital stay (LOS) measured in days of hospitalization from study inclusion until two weeks after delivery during pregnancy and postpartum. Secondary outcomes are patient-reported psychological well-being, health-related quality of life, satisfaction with care, and number of antenatal contacts and visits. Exploratory outcomes will be pregnancy and delivery outcomes.

Hypothesis
The trial was designed to evaluate the effect of a midwife-coordinated, individualized and specialized maternity care intervention provided to pregnant women with chronic diseases. We hypothesize that this complex intervention with all its components will have a positive impact on the self-reported psychological well-being of the participants, increase the health-related quality of life and the satisfaction with the care provided, and enhance the participants’ ability to cope with everyday life during pregnancy and in the immediate postpartum period. We hypothesize that the sum of these components will reduce the total number of days of hospitalization.

Previous trials with complex maternity care interventions with nurse-specialists and midwifery continuity of care models have showed a reduction in LOS. Tracy et al. showed a mean reduction in LOS of 0.38 days (95% CI 0.18-0.56) in the postnatal hospital stay among a population of mixed-risk pregnant women (n=1748). We expect that the reduction in LOS will be greater in this trial with a population of high-risk pregnant women with chronic disease. In addition, we measure LOS both antenatally and postpartum from the time of up until 2 weeks after delivery.

Methods
Study design
The ChroPreg trial is a two-arm parallel-group investigator-initiated RCT. Participants will be randomized to either a midwife-coordinated, individualized, and specialized maternity care intervention (ChroPreg) as an add-on intervention to standard care or standard care alone with a 1:1
allocation. The trial is designed in accordance with the *Consolidated Standards of Reporting Trials* (CONSORT) guidelines for RCTs (28), extended in the *Better reporting of interventions: template for intervention description and replication* (TIDieR) checklist and guide (29), and in accordance with the *Standard Protocol Items: Recommendations for Interventional Trials* (SPIRIT) guidelines for reporting trial protocols (30).

**Study setting**

The study will take place at the Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. The department is highly specialized and in addition to serving as a birth facility for women living in the local area of the hospital in Copenhagen, it is a tertiary referral center for a large geographical area. In 2017, 5471 women gave birth at the hospital and 700 of these women had one or more chronic diseases. Participants will be recruited among the women attending antenatal care at Rigshospitalet. In Denmark, all women with normal pregnancies receive antenatal care primarily from midwives, whereas pregnant women with chronic disease and complicated pregnancies receive obstetrician-led antenatal care including consultations with midwives.

**Inclusion and exclusion criteria**

The Danish Health Authorities define chronic disease as a prolonged disease or a disease that continuously recurs (31). Eligible participants will be: pregnant women with one or more chronic diseases diagnosed before pregnancy and for which the pregnant woman is followed by an obstetrician during pregnancy, ≥18 years, able to understand spoken and written Danish, give informed consent, pregnant with a single live fetus, and be between week 12 and 19 of pregnancy at time of inclusion. Potential participants will be excluded from the study for the following reasons: multiple pregnancy, substance abuse, psychiatric disease as the only chronic disease, and pregnant women with diabetes and heart disease (these women already receive specialized care programs at Rigshospitalet).
Recruitment procedure

As a part of the standard antenatal care contacts, women who fulfill the study criteria will be invited to participate in the study by a midwife from the antenatal clinic responsible for the coordination of specialized antenatal care. Eligible participants who verbally consent to receiving more information about the study will be given written information, and subsequently be contacted by telephone by one of the investigators. If the woman is still interested in receiving information about the study, preliminary questions will be answered. Thereafter, the woman is given the choice between a face-to-face meeting at the hospital or receiving additional information by telephone. At the face-to-face meeting or during the telephone conversation, more detailed verbal information about the study will be provided by one of the investigators and the potential study candidate will have the opportunity to ask further questions about the study. If the woman decides to participate, written informed consent will be obtained by the investigator, and the baseline questionnaire will be completed. The randomization and allocation to one of the two RCT arms will be carried out by one of the investigators. The choice between mode of receiving information either by telephone or face-to-face is provided to accommodate women who do not live near the hospital or have other reasons to prefer receiving information by telephone. A Danish RCT study tested the effect of face-to-face versus telephone information when including study participants and found no differences in level of comprehension between the two groups (32).

Randomization and blinding

After verbal and written informed consent is obtained the participants are randomized by one of the investigators to either the ChroPreg intervention plus standard care or standard care alone in a ratio of 1:1. The allocation sequence is computer-generated and non-stratified with a varying block sizes concealed to the researchers. The allocation will be centrally conducted using the online clinical trial management and randomization system EasyTrial (easytrial.net, Aalborg, Denmark). After allocation the participants will be informed about the allocation and further plan of the trial. The specialized
midwives who will deliver the intervention will not be blinded to the allocation and neither will the participants. However, the research staff who will collect data from medical records and questionnaires will be blinded to treatment allocation, as will the chief investigator (HKH) and the trial statistician (SR).

Sample size calculation
A total of 258274 women will be enrolled in the study. The sample size was determined using unpublished data on 426 pregnant women with chronic diseases hospitalized at Rigshospitalet during pregnancy and in the post-partum period in 2017. The average length of hospital stay (LOS) during pregnancy was 3.9 days; however, due to a right-skewed distribution, log-transformed LOS was used as the outcome for the sample size calculation. Therefore, the effect of the intervention is expressed as a ratio. We expect a reduction of 25% in LOS in the intervention group compared to the control group. This corresponds approximately to a mean reduction of 1 day of hospitalization and to an improvement of \( \log(1-0.25) = -0.29 \) on the log scale, which we consider a realistic and clinically significant effect size, corresponding to an improvement of \( \log(1-0.25) = -0.29 \) on log scale. The SD of number of days in hospital on log scale was 0.80. With a difference of 0.29, SD = 0.80, a power of 0.8 and a significance level of 0.05, an analysis by the two-sample t-test requires 123 women in each group. We expect a maximum of 10%5% to be lost to follow-up, leading to a total of 137129 women needing to be enrolled in each group.

The intervention

*Standard care alone*

Participants allocated to the control group will receive standard care alone. Pregnant women with chronic disease are considered to have high-risk pregnancies and are referred to the appropriate level of specialized maternity care. All pregnant women with chronic disease will be followed by an obstetrician and an individual care plan is designed considering the character and severity of the disease and the pregnancy associated risks. Routinely in Denmark, all pregnant women including pregnant women with chronic diseases are also followed by midwives during pregnancy. The standard
care appointments for midwife consultation are timed approximately around weeks:14–18, 28, 35, 38, and 40 and include physical examinations, discussion about lifestyle, symptoms of normal and complicated pregnancy, breastfeeding and preparation for delivery. At Rigshospitalet, two auditorium prenatal classes (2 x 90 minutes) are delivered by a midwife. The classes provide information about what to expect during birth (contractions, pain relief, possible complications and interventions) and in the puerperium (breastfeeding and family building) At Rigshospitalet, all pregnant women are offered two auditorium prenatal classes delivered by a midwife. After childbirth, women can contact the department and request a conversation about the delivery with a midwife, and women who have experienced severe or unexpected complications may be offered a postnatal consultation with an obstetrician.

*The ChropPreg intervention plus standard care*

The ChroPreg intervention is designed based on a review of the literature on complex interventions in maternity care (19-21) and aimed to fit the needs of women with chronic disease. Complex interventions (33) consist of a number of components that may work independently and interdependently, and it can be difficult to identify the “active ingredient” of the intervention, rendering it even more important to describe the different components, the hypothesized mechanism behind each component, and the interaction between the components (33). The three main components of the ChroPreg intervention are described in more detail below. The ChroPreg intervention is provided by specialized midwives (SM). In addition to the standard care outlined above, women in the intervention group will receive additional antenatal consultations, postpartum follow-up and care coordination. Both standard care midwife consultations and the extra consultations will be provided by the same SM (content described below and Table 1).

1. *Midwife-coordinated and individualized care*

The participant will be seen by the same SM throughout the study period. For all women in the intervention group, it will be recorded how many consultations were covered by the SM. pregnancy, and in the postpartum period. During the study period, the SM will identify the special needs and
wishes of each woman and will discuss the optimal care of the woman with the obstetrician responsible for her medical care. The SM will be assisting the participants in coordinating antenatal visits to fit their everyday life and to avoid unnecessary hospital visits and in communicating with other care providers, who are part of the standard Danish healthcare system (e.g. general practitioner and health visitor) as well as other health care professionals from other departments at the hospital. The participants can contact the SM by e-mail and during weekly phone hours. If the participant is hospitalized during pregnancy the SM will contact the woman by phone and arrange an appointment. Assisting the participants when in labor is not a part of the intervention.

2. Additional ante and postpartum consultations

In addition to the standard care, two additional antenatal consultations will be scheduled with the SM at 20–24 and 30–33 weeks of pregnancy to discuss psychological well-being in pregnancy, breastfeeding and individualized preparation for childbirth, and postpartum care. The purpose is to support the woman’s own capacity to handle her pregnancy, childbirth and everyday life as a new mother with a chronic disease. If the need arises, the SM can refer the woman to a psychologist at the hospital for additional consultation. After birth, the SM follows up on the psychological well-being during the planned telephone support postpartum, and 4–6 weeks after birth, a consultation is planned with the SM to discuss the woman’s overall experience and issues important to the woman regarding her pregnancy and delivery.

3. Specialized midwives (SM)

Before initiation of the study, The SMs have all attended a 3-day training delivered by medical specialists from the hospital handling the care for pregnant women with various chronic diseases. in chronic disease and pregnancy. The training includes basic medical knowledge on lupus erythematosus, rheumatoid arthritis, lung disease, kidney disease, hypertension, multiple sclerosis, epilepsy and other neurological diseases, inflammatory bowel disease, hematological diseases, and thyroid disease. Additional topics in the training program are: pre-pregnancy counseling, pathophysiology, pregnancy complications, symptoms of disease in relation to pregnancy, obstetric treatment, medication and drug safety, lactation, and interdisciplinary collaboration. The training also
includes psychological aspects of pregnancy complicated by chronic disease. Topics covered in the program are: psychological development during pregnancy, signs and symptoms of depression and anxiety during pregnancy and postpartum, prenatal attachment, and facilitating conversations about the woman’s experience of childbirth. Furthermore, the SMs will receive training in how to best support pregnant women in coping with the everyday challenges of pregnancy and their new role as a mother when living with a chronic disease. This part of the training is delivered by midwives with further education in psychology and clinical psychologists. A manual that outlines the content of all consultations with the SM and topics covered during the consultations for all activities in the intervention will be developed and used as a tool by the SMs. To secure intervention fidelity, observations of the SMs consultations are carried out by one of the investigators in order to give feedback.

Table 1. Description of planned midwife-activities in the ChroPreg intervention group and standard

Table 1. should be placed here (located at the end of this document)

Outcome measures
Data will be collected from medical records and using electronic self-administered questionnaires, and. Data will be obtained at baseline (t1) and three times during the study period: at 33–37 weeks of gestation (t3), at two weeks after delivery (t4), and at two months after delivery (t5). The participants will complete the first electronic questionnaire after signing the informed consent to participate and before randomization. The subsequent questionnaires will be sent as a link in an e-mail.

Figure 2. Consolidated Standards of Reporting Trials (CONSORT) showing time points of enrollment, intervention, and outcome measures

Primary outcome
The primary outcome is Length of Hospital Stay (LOS) measured as the number of days (mean and standard deviation (SD)) spent in hospital from inclusion into the study during pregnancy and until two
weeks after delivery. All participants are expected to have a minimum of 1 day of hospital stay in relation to the delivery, as this population is a high-risk population where home birth is advised against. Should a woman nevertheless have an unplanned homebirth she will expectedly be transferred to the hospital for postpartum.

LOS was chosen as the primary outcome, because it is a widely used outcome in health care research (34, 35). For this trial, a reduction in LOS covers at least two important outcomes in health care research: 1: the patient perspective with a reduced need for hospitalization which is an expression for better quality of healthcare received by the patients, and 2: the health economic perspective with reduced health costs in connection with days of hospitalization (34, 35). Data will be collected from patient records two weeks after delivery.

Secondary outcomes

1. Psychological well-being

a. WHO (Five) Well-Being Index (WHO-5) (36) measures current (e.g. preceding two weeks) psychological well-being and consists of 5 positively phrased items, each scored on a Likert scale (0 = none of the time, 5 = all the time). The raw score ranges from 0, indicating the lowest possible well-being, to 25, indicating the highest possible well-being. This score is multiplied by a factor of 4, creating a score ranging from 0–100 with 100 being the highest possible well-being. WHO-5 has high psychometric validity and it can be used as an outcome measure in clinical trials (36).

b. Edinburgh Postnatal Depression Scale reported scale consisting of 10 items scored on a 4-point Likert scale (0–3) concerning intensity of depressive mood and symptoms during the last seven days (0 indicates absence of depressive mood and/or symptoms and 3 indicates the worst mood and/or symptoms on a given item). The lowest overall score is 0 and the highest overall score is 30 (cut-off scores included will be ≥10 and ≥13) . Cut-off scores for likelihood of clinical depression have been suggested to be at ≥10 and ≥13 (37, 38) and therefore we include both cut-offs scores in our statistical analysis to avoid the risk of failed detection of cases. The EPDS has been validated for use
as a detection tool for antenatal and postnatal depression (38, 39) and it has been translated and used into Danish research (40)

c. *Cambridge Worry Scale* (CWS) (41) measures pregnant women’s degree of worry during pregnancy. The questionnaire consists of 16 items concerning different areas of possible worry on a 6-point Likert scale (0 = no worry, 5 = highest degree of worry). The scale ranges from 0 to 60 with 60 indicating the highest possible level of worry. CWS has a high internal validity and reliability and has been utilized in clinical studies including populations of women with high-risk pregnancies (42, 43).

2. Health-Related Quality of life (HRQoL) and self-rated health

*SF-12* (44) is an abridged version of the 36-Item Short Form Survey questionnaire developed to measure health-related quality of life and thereby self-rated health in a single item. The instrument is well-validated and reliable and widely used including during pregnancy and in the postpartum period (44, 45). The SF-12 questionnaire consists of 12 items that measure physical and mental health, divided into eight subscales: physical and social functioning, role limitation due to physical and mental health, bodily pain, general health perceptions (self-rated health), vitality, and mental health. The scores from the subscales can be calculated in two overall scores: Physical Component Summary (PCS) and Mental Component Summary (MCS) with higher scores indicating better health-related quality of life (44).

3. Patient satisfaction

*The Pregnancy and Childbirth Questionnaire (PCQ)* (46) contains two subscales: 1) pregnancy-related items (18 items) covering two domains, personal treatment and patient education/information, and 2) birth-related items (7 items). The PCQ consists of 25 items rated on a 5-point Likert scale (1 = totally agree, 5 = totally disagree). Higher scores indicate higher patient satisfaction with quality of care. The questionnaire has been rated to have good internal consistency and reliability (47).

4. Health-economic outcomes

a. *Antenatal contacts* (measured as number of scheduled and unscheduled visits with obstetric doctors and midwives and telephone consultations).
Exploratory outcomes

5. Pregnancy and delivery outcomes

Pregnancy and delivery outcomes will be tracked for the purposes of this study. Exploratory outcomes are considered to be hypothesis generating.

*Pregnancy complications* (gestational diabetes, pregnancy-induced hypertension, preeclampsia) (yes/no); *labor onset* (spontaneous or induced); *preterm delivery* (yes/no); *mode of delivery* (percentage of participants with spontaneous vaginal delivery, or caesarean section (planned or emergency)); *use of labor analgesia* (no analgesia/any analgesia, epidural analgesia (yes/no)); *outpatient telemonitoring for pregnancy complications* (yes/no and duration (days)); *newborn’s well-being at time of delivery* (Apgar score ≤7 at 5 minutes postpartum (yes/no)); *newborn’s birth weight* (measured in kilograms); *breastfeeding* (intention to breastfeed (yes/no); breastfeeding two months after delivery (yes/no); and intended duration (months) of breastfeeding).

Data analysis

Analyses are to be performed based on the intention-to-treat principle. Unadjusted and adjusted The log-transformed number of days in hospital in the two groups will be compared in the primary unadjusted analysis and in a secondary analysis, adjustments will be made for parity and age. Analysis will be performed using the general linear model unless we find a generalized linear model comparisons of log-transformed number of days in hospital in the two groups will be performed using the general linear model; however, optionally, a generalized linear model (e.g. Poisson or negative binomial) to will be used if we find such a model to fit better to fit the distribution of the number of days in hospital. Furthermore, the two groups will be compared with respect to the proportion of women with three or fewer days in hospital. Comparison of secondary and exploratory outcomes will similarly be performed using the general or generalized linear models as appropriate. In case of an uneven allocation of pregnancies with congenital malformations or chromosomal abnormalities to the two groups, analyses will be performed in the sub group of women without pregnancies with congenital malformations or chromosomal abnormalities. Missing data techniques (e.g. multiple
imputation) will be employed if a substantial amount of the data is missing.

Discussion

The WHO estimates that chronic disease is the cause of the majority of premature deaths in the world and that most of these could be prevented by giving people better access to appropriate health care and treatment and by reducing modifiable risk factors such as diet, exercise and smoking (2). Worldwide, the proportion of women of childbearing age living with one or more chronic diseases is growing (3, 5), and pregnancies affected by chronic disease are associated with a higher risk of complications (6, 10) and poor psychological health (8, 48). The perinatal period is a theoretically favorable time in a woman’s life to implement effective preventive and health promoting interventions to women (49). Interventions delivered in the perinatal period can therefore hypothetically reduce the potentially negative health impact in pregnancy caused by chronic disease and possibly also empower and strengthen the women’s long-term self-care ability with their chronic disease. The ChroPreg trial is highly relevant, and to the best of our knowledge, the largest scale RCT designed to investigate the effect of a midwife-coordinated, individualized and specialized maternity care add-on intervention for pregnant women with chronic diseases on LOS, patient-reported outcomes, and, pregnancy and delivery outcomes obstetric, and health economic outcomes. Systematic reviews of RCTs have found previous complex maternity care interventions to be cost-effective compared to standard care (24, 25). However, in these reviews, the authors have called for trials that evaluate psychological well-being and patient satisfaction with maternity care with validated psychometric instruments (19, 27). Therefore, in this RCT we utilize validated patient-reported questionnaires to estimate psychological well-being during pregnancy and postpartum (36, 37, 41), health-related quality of life (44), and patient satisfaction with maternity care (46). In this trial we will also combine face-to-face consultations with add-on telephone support and e-mail correspondence delivered by the SM who follow the participants throughout pregnancy and postpartum. Telephone support during pregnancy and after birth has been suggested to be of benefit to women at risk of depression, reducing signs of depression and facilitating breastfeeding initiation and continuation (26). However, these interventions have not yet been tested among pregnant women with chronic diseases, and therefore
the results from this trial may inform us on how to design future woman-centered and cost-effective interventions for women with chronic disease. This trial will also provide information to clinicians about the feasibility of prolonging the midwifery care with consultations and more thorough follow-up after discharge from hospital, as this care at present is primarily delivered by health visitors in Denmark.

As this is a low-risk intervention adding to standard care and not involving any known side effects, we anticipate that most eligible women with chronic disease will be interested in participating in the trial, and we do not expect a high level of drop-outs. Measures to monitor and enhance adherence to the intervention will be taken. The two self-reported questionnaires, one at 33–37 weeks of pregnancy and one at two months postpartum will be followed up with reminders if not completed within the time frame, and text message reminders will be sent in advance; adherence to all planned activities of the interventions will be monitored and recorded. The primary outcome (LOS) data is collected from medical records and does not rely on patient reporting. To reduce avoid the risk of selection bias, eligible women will be offered the choice between a face-to-face meeting or a telephone conversation for information about the study, informed consent, and randomization, accommodating women living farther from the hospital. The ChroPreg trial will provide an extensive evaluation of a coordinated, individualized and specialized maternity care intervention for pregnant women with chronic diseases. The results from this trial will be among the first of its kind and will help clinicians and policy makers to make evidence-based decisions when developing and implementing efficient, woman-centered and cost-effective maternity care interventions for women with chronic disease.

To conclude, this paper outlines the background, aim, and methods of an RCT in which the ChroPreg intervention plus standard care is compared with standard care alone in a population of pregnant women with chronic disease. We hypothesize that the sum of active components in the ChroPreg intervention will reduce the overall need for hospitalization and enhance the psychological well-being and satisfaction with care for the participants.
Trial status

Recruitment of participants was initiated October 1, 2018 and the current number of enrolled participants is in line with what was expected from our calculations. Recruitment and is anticipated to continue until January 31, 2020, and data collection will be concluded by June 1, 2020. No interim analyses will be performed.

Abbreviations

CONSORT: Consolidated Standards of Reporting Trials

LOS: Length of Hospital Stay

SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)

TIDieR: Better reporting of interventions: template for intervention description and replication

SM: Specialized midwives

RM: Regular midwife

GP: General practitioner

SD: Standard deviation

WHO-5: WHO (Five) Well-Being Index

EPDS: Edinburgh Postnatal Depression Scale

CWS: Cambridge Worry Scale

HRQoL: Health-Related Quality of life

PCS: Physical Component Summary

MCS: Mental Component Summary
PCQ: The Pregnancy and Childbirth Questionnaire

Declarations

Ethics approval and consent to participate

The trial protocol has been reviewed by the Regional Committee on Health Research Ethics (Jr. no. H-18015521). The intervention was assessed to be a low-risk add-on intervention to the standard care offered to pregnant women with chronic disease, and the board has judged that no known risk is involved with participating in the trial. The Regional Committee on Health Research Ethics have therefore concluded that the study can be initiated without further ethical approval. The trial will be carried out in accordance with the principles of the National Committee on Health Research Ethics in Denmark (50) and the principles of the Helsinki Declaration (51). Written informed consent will be obtained, and all participants will be informed about the voluntary nature of their participation and their right to withdraw from the study. No side-effects or harms to the participants are anticipated. However, if participants wish to withdraw from the trial, their data will not be included in the final analysis, but they will continue to receive standard care. If a participant wishes to withdraw from the trial, she will be asked for permission to retain her data for the final analysis. All data from participants will be handled anonymously and secured in a logged database. The trial has been approved by the Danish Data Protection Agency (Jr. no.: RH_2017-346. L-suite no.: 06055). If any important protocol modifications are made, these will be reported in the trial registry (ClinicalTrials.org).

Consent for publication

N/A

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Competing interests

The authors declare that they have no competing interests.

Funding

The study has received funding from the Research Council of the Danish Regions and from the Augustinus Foundation. The article presents independent research and the sponsor and funding body did not have any influence on the design or planning of the study and will not have any role in the conduct of the study, the interpretation of the results, or in the writing of the manuscript.

Authors’ contributions

HKH is the chief investigator of the trial. HKH and MW designed the trial and coordinated the main preparation of study documents and the funding application. MW, MJ, ASE, AB, JM, AT, SR, and HKH contributed to the funding application and the study design. MW drafted the first version of the manuscript. All authors have been involved in revising the manuscript critically for important intellectual content and have given final approval of the version to be published.

Acknowledgements

Not applicable.

References

1. Danish Health Authorities IJS, editor. Kronisk sygdom. Patient, sundhedsvæsen og samfund. Chronic disease. Patient, healthcare system and society. Copenhagen: Danish Health and Medicines Authority. Copenhagen: Danish Health Authorities, 2005.

2. (WHO) WHO. Noncommunicable Diseases Progress Monitor, 2017. Licence: CC BY-NC-SA 3.0 IGO. Geneva2017.
3. Jolving LR, Nielsen J, Kesmodel US, Nielsen RG, Beck-Nielsen SS, Norgard BM. Prevalence of maternal chronic diseases during pregnancy - a nationwide population based study from 1989 to 2013. Acta obstetricia et gynecologica Scandinavica. 2016;95(11):1295-304.

4. Chatterjee S, Kotelchuck M, Sambamoorthi U. Prevalence of chronic illness in pregnancy, access to care, and health care costs: implications for interconception care. Womens Health Issues. 2008;18(6 Suppl):S107-S16.

5. Kersten I, Lange AE, Haas JP, Fusch C, Lode H, Hoffmann W, et al. Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC pregnancy and childbirth. 2014;14:75.

6. Narayan B, Jarvis S, Dassan P, Nelson-Piercy C. Medical problems in pregnancy. Clinical medicine (London, England). 2018;18(1):108-11.

7. Jolving LR, Nielsen J, Beck-Nielsen SS, Nielsen RG, Friedman S, Kesmodel US, et al. The Association Between Maternal Chronic Inflammatory Bowel Disease and Long-term Health Outcomes in Children-A Nationwide Cohort Study. Inflammatory bowel diseases. 2017;23(8):1440-6.

8. Bjork MH, Veiby G, Reiter SC, Berle JO, Daltveit AK, Spigset O, et al. Depression and anxiety in women with epilepsy during pregnancy and after delivery: a prospective population-based cohort study on frequency, risk factors, medication, and prognosis. Epilepsia. 2015;56(1):28-39.

9. Bendix J, Hegaard HK, Langhoff-Roos J, Bergholt T. Changing prevalence and the risk factors for antenatal obstetric hospitalizations in Denmark 2003-2012. Clinical epidemiology. 2016;8:165-75.

10. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348:g2301.

11. Viale L, Allotey J, Cheong-See F, Arroyo-Manzano D, McCorry D, Bagary M, et al. Epilepsy in
pregnancy and reproductive outcomes: a systematic review and meta-analysis. Lancet (London, England). 2015;386(10006):1845-52.

12. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. ClinJAmSocNephrol. 2010;5(11):2060-8.

13. Jara LJ, Medina G, Cruz-Dominguez P, Navarro C, Vera-Lastra O, Saavedra MA. Risk factors of systemic lupus erythematosus flares during pregnancy. Immunologic research. 2014;60(2-3):184-92.

14. de Man YA, Dolhain RJ, Hazes JM. Disease activity or remission of rheumatoid arthritis before, during and following pregnancy. Current opinion in rheumatology. 2014;26(3):329-33.

15. Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstetrics and gynecology. 2014;124(6):1157-68.

16. de Wolff M, Ersboll AS, Hegaard H, Johansen M, Gustafsson F, Damm P, et al. Psychological adaptation after peripartum cardiomyopathy: A qualitative study. Midwifery. 2018;62:52-60.

17. Thomas H. Women's postnatal experience following a medically complicated pregnancy. Health care for women international. 2004;25(1):76-87.

18. Weckesser A, Denny E. Women living with epilepsy, experiences of pregnancy and reproductive health: a review of the literature. Seizure. 2013;22(2):91-8.

19. Kroll-Desrosiers AR, Crawford SL, Moore Simas TA, Rosen AK, Mattocks KM. Improving Pregnancy Outcomes through Maternity Care Coordination: A Systematic Review. Womens Health Issues. 2016;26(1):87-99.
20. Schmied V, Mills A, Kruske S, Kemp L, Fowler C, Homer C. The nature and impact of collaboration and integrated service delivery for pregnant women, children and families. Journal of clinical nursing. 2010;19(23-24):3516-26.

21. Rodriguez C, des Rivieres-Pigeon C. A literature review on integrated perinatal care. International journal of integrated care. 2007;7:e28.

22. Bryant-Lukosius D, Carter N, Reid K, Donald F, Martin-Misener R, Kilpatrick K, et al. The clinical effectiveness and cost-effectiveness of clinical nurse specialist-led hospital to home transitional care: a systematic review. Journal of evaluation in clinical practice. 2015;21(5):763-81.

23. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Annals of surgery. 2008;248(2):189-98.

24. Little M, Saul GD, Testa K, Gaziano C. Improving pregnancy outcome and reducing avoidable clinical resource utilization through telephonic perinatal care coordination. Lippincott's case management : managing the process of patient care. 2002;7(3):103-12.

25. Tracy SK, Hartz DL, Tracy MB, Allen J, Forti A, Hall B, et al. Caseload midwifery care versus standard maternity care for women of any risk: M@NGO, a randomised controlled trial. Lancet (London, England). 2013;382(9906):1723-32.

26. Lavender T, Richens Y, Milan SJ, Smyth RM, Dowswell T. Telephone support for women during pregnancy and the first six weeks postpartum. The Cochrane database of systematic reviews. 2013(7):Cd009338.

27. Sandall J, Soltani H, Gates S, Shennan A, Devane D. Midwife-led continuity models versus other models of care for childbearing women. The Cochrane database of systematic reviews. 2015(9):Cd004667.
28. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. International journal of surgery (London, England). 2011;9(8):672-7.

29. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. [Better Reporting of Interventions: Template for Intervention Description and Replication (TIDieR) Checklist and Guide]. Gesundheitswesen (Bundesverband der Arzte des Öffentlichen Gesundheitsdienstes (Germany)). 2016;78(3):175-88.

30. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krle AJK, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Revista panamericana de salud publica = Pan American journal of public health. 2015;38(6):506-14.

31. Sundhedsstyrelsen DHA. Den generiske model for forløbsprogrammer for kronisk sygdom. Copenhagen: Sundhedsstyrelsen, 2012.

32. Foss KT, Kjaergaard J, Stensballe LG, Greisen G. Recruiting to Clinical Trials on the Telephone - a randomized controlled trial. Trials. 2016;17(1):552.

33. Counsil MR. Developing and evaluating complex interventions: new guidance. London: Medical Research Counsil, 2006.

34. Lingsma HF, Bottle A, Middleton S, Kievit J, Steyerberg EW, Marang-van de Mheen PJ. Evaluation of hospital outcomes: the relation between length-of-stay, readmission, and mortality in a large international administrative database. BMC Health Serv Res. 2018;18(1):116.

35. Campbell OM, Cegolon L, Macleod D, Benova L. Length of Stay After Childbirth in 92 Countries and Associated Factors in 30 Low- and Middle-Income Countries: Compilation of Reported Data and a Cross-sectional Analysis from Nationally Representative Surveys. PLoS Med. 2016;13(3):e1001972.

36. Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic
review of the literature. Psychotherapy and psychosomatics. 2015;84(3):167-76.

37. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. The British journal of psychiatry: the journal of mental science. 1987;150:782-6.

38. Glaze R, Cox JL. Validation of a computerised version of the 10-item (self-rating) Edinburgh Postnatal Depression Scale. Journal of affective disorders. 1991;22(1-2):73-7.

39. Tendais I, Costa R, Conde A, Figueiredo B. Screening for depression and anxiety disorders from pregnancy to postpartum with the EPDS and STAI. The Spanish journal of psychology. 2014;17:E7.

40. Nielsen Forman D, Videbech P, Hedegaard M, Dalby Salvig J, Secher NJ. Postpartum depression: identification of women at risk. BJOG: an international journal of obstetrics and gynaecology. 2000;107(10):1210-7.

41. Green JM, Kafetsios K, Statham HE, Snowdon CM. Factor structure, validity and reliability of the Cambridge Worry Scale in a pregnant population. Journal of health psychology. 2003;8(6):753-64.

42. Asplin N, Wessel H, Marions L, Georgsson Ohman S. Maternal emotional wellbeing over time and attachment to the fetus when a malformation is detected. Sex Reprod Healthc. 2015;6(3):191-5.

43. Petersen JJ, Paulitsch MA, Guethlin C, Gensichen J, Jahn A. A survey on worries of pregnant women-testing the German version of the Cambridge worry scale. BMC Public Health. 2009;9:490.

44. Loosman WL, Hoekstra T, van Dijk S, Terwee CB, Honig A, Siegert CE, et al. Short-Form 12 or Short-Form 36 to measure quality-of-life changes in dialysis patients? Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2015;30(7):1170-6.
45. Vinturache A, Stephenson N, McDonald S, Wu M, Bayrampour H, Tough S. Health-related quality of life in pregnancy and postpartum among women with assisted conception in Canada. Fertility and sterility. 2015;104(1):188-95.e1.

46. Truijens SE, Pommer AM, van Runnard Heimel PJ, Verhoeven CJ, Oei SG, Pop VJ. Development of the Pregnancy and Childbirth Questionnaire (PCQ): evaluating quality of care as perceived by women who recently gave birth. EurJObstetGynecolReprodBiol. 2014;174:35-40.

47. Nilver H, Begley C, Berg M. Measuring women's childbirth experiences: a systematic review for identification and analysis of validated instruments. BMC pregnancy and childbirth. 2017;17(1):203.

48. Brown HK, Qazilbash A, Rahim N, Dennis CL, Vigod SN. Chronic Medical Conditions and Peripartum Mental Illness: A Systematic Review and Meta-Analysis. Am J Epidemiol. 2018;187(9):2060-8.

49. Haakstad LA, Voldner N, Bo K. Stages of change model for participation in physical activity during pregnancy. J Pregnancy. 2013;2013:193170.

50. Komitéloven (2017). Bekendtgørelse af lov om videnskabsetisk behandling af sundhedsvidskabelige forskningsprojekter, LBK nr. 1083 af 15/9/2017 (2017).

51. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. The Journal of the American College of Dentists. 2014;81(3):14-8.

Tables

Table 1. Description of planned midwife-activities in the ChroPreg intervention group and standard care group.

| ChroPreg intervention + standard care | Objective of activity | Standard care alone | Objective of activity |
|---------------------------------------|-----------------------|---------------------|-----------------------|
| **During pregnancy**                  |                       |                     |                       |
| Week 14-18                            | Medical history taking, follow up on information from general practitioner | Week 14-18 | Medical history taking, follow up on information from general practitioner |
| Midwife appointment                    | Midwife appointment   |                     |                       |
| Time Period | Appointment Type | Duration | Location | Description |
|-------------|------------------|----------|----------|-------------|
| Week 20-24  | Midwife appointment | 60 minutes | SM | Specialized midwife (SM) At the hospital | Focus on psychological well-being during pregnancy and preparation for breastfeeding. The consultation will be centered around the woman's experience of pregnancy, physical development, prenatal attachment, the interaction between pregnancy and chronic disease, normal pregnancy signs and symptoms and thoughts about breastfeeding. |
| Week 28-30*| Midwife appointment | 30 minutes | SM | At the hospital | Conversation about breastfeeding, rhesus prophylaxis, well-being and symptoms of pregnancy and chronic disease. |
| Week 30-33 | Midwife appointment | 60 minutes | SM | At the hospital | Focus on individual childbirth preparation and postpartum care. Information about birthing options and pain relief and management. The individual needs and wishes of the woman will be discussed and an individual birth plan will be made. |
| Week 35-36 | Midwife appointment | 30 minutes | SM | At the hospital | Consultation about pregnancy, well-being, symptoms of chronic disease and the coming birth. |
| Week 38-39 | Midwife appointment | 30 minutes | SM | At the hospital | Consultation about pregnancy, well-being, symptoms of chronic disease, the coming birth and postpartum care and follow-up. |
|            | Regular midwife (RM) | 30 minutes | At the hospital | Conversation about breastfeeding, rhesus prophylaxis, well-being and symptoms of pregnancy. |
| Week 40 | At the hospital |
|---------|----------------|
| Midwife appointment | Consultation about coming birth, pregnancy and signs of labor, discussion about induced labor |
| 30 minutes | Internal vaginal examination if woman wishes to |

| Postpartum follow-up |
|----------------------|
| 1st and 2nd week after discharge from hospital |
| 30-60 minutes |
| SM |
| Telephone |
| Postpartum follow-up on breastfeeding, chronic disease management, medication, and psychological well-being. |
| Coordination with primary health care workers if needed (GP/health visitor/medical specialists). |

| Activities throughout the study period |
|---------------------------------------|
| E-mail correspondence | The woman can contact the specialized midwife by e-mail. This contact may concern all relevant issues during pregnancy and postpartum. |
| Weekly telephone hours |
| From inclusion to end of study period |
| SM | Women can contact the coordinating midwife department with questions and concerns. |
if further visits will be needed in addition to the telephone contacts.

*All standard midwife appointments from week 28 and on include urine testing for glucose and protein and measuring of blood pressure (screening for indicators for gestational diabetes and pre-eclampsia) and physical examinations (measuring the size, heart beat and position of the fetus).

Figures

**Figure 1**
The expected flow diagram of progress through the ChroPreg trial.

**Figure 2**
Consolidated Standards of Reporting Trials (CONSORT) showing time points of enrollment, intervention, and outcome measures.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

TIDieR-Checklist-PDF. 18.12.18.pdf
SPIRIT_Fillable-checklist-18.12.18.doc